OptimizeRxOPRX
About: OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
Employees: 136
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 27
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
5.18% less ownership
Funds ownership: 72.76% [Q2] → 67.58% (-5.18%) [Q3]
8% less funds holding
Funds holding: 92 [Q2] → 85 (-7) [Q3]
28% less capital invested
Capital invested by funds: $133M [Q2] → $95.6M (-$37.4M) [Q3]
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
95% less call options, than puts
Call options by funds: $7K | Put options by funds: $140K
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
JMP Securities Constantine Davides 31% 1-year accuracy 9 / 29 met price target | 42%upside $8 | Market Outperform Reiterated | 6 Feb 2025 |
RBC Capital Sean Dodge 59% 1-year accuracy 27 / 46 met price target | 7%upside $6 | Sector Perform Downgraded | 8 Jan 2025 |
Lake Street Eric Martinuzzi 57% 1-year accuracy 13 / 23 met price target | 95%upside $11 | Buy Reiterated | 24 Dec 2024 |
B. Riley Securities Neil Chatterji 100% 1-year accuracy 2 / 2 met price target | 131%upside $13 | Buy Maintained | 24 Dec 2024 |
Stephens & Co. Jeff Garro 50% 1-year accuracy 3 / 6 met price target | 2%downside $5.50 | Equal-Weight Initiated | 20 Dec 2024 |
Financial journalist opinion









